306 related articles for article (PubMed ID: 22498430)
21. Development of a phenotypic susceptibility assay for HIV-1 integrase inhibitors.
Heger E; Theis AA; Remmel K; Walter H; Pironti A; Knops E; Di Cristanziano V; Jensen B; Esser S; Kaiser R; Lübke N
J Virol Methods; 2016 Dec; 238():29-37. PubMed ID: 27737783
[TBL] [Abstract][Full Text] [Related]
22. Novel inhibitors of HIV-1 integration.
Witvrouw M; Van Maele B; Vercammen J; Hantson A; Engelborghs Y; De Clercq E; Pannecouque C; Debyser Z
Curr Drug Metab; 2004 Aug; 5(4):291-304. PubMed ID: 15320701
[TBL] [Abstract][Full Text] [Related]
23. 2-Hydroxyisoquinoline-1,3(2H,4H)-diones (HIDs), novel inhibitors of HIV integrase with a high barrier to resistance.
Desimmie BA; Demeulemeester J; Suchaud V; Taltynov O; Billamboz M; Lion C; Bailly F; Strelkov SV; Debyser Z; Cotelle P; Christ F
ACS Chem Biol; 2013; 8(6):1187-94. PubMed ID: 23517458
[TBL] [Abstract][Full Text] [Related]
24. Structural Comparison of Diverse HIV-1 Subtypes using Molecular Modelling and Docking Analyses of Integrase Inhibitors.
Isaacs D; Mikasi SG; Obasa AE; Ikomey GM; Shityakov S; Cloete R; Jacobs GB
Viruses; 2020 Aug; 12(9):. PubMed ID: 32858802
[TBL] [Abstract][Full Text] [Related]
25. Elvitegravir: a new HIV integrase inhibitor.
Shimura K; Kodama EN
Antivir Chem Chemother; 2009 Oct; 20(2):79-85. PubMed ID: 19843978
[TBL] [Abstract][Full Text] [Related]
26. Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile.
Tsiang M; Jones GS; Goldsmith J; Mulato A; Hansen D; Kan E; Tsai L; Bam RA; Stepan G; Stray KM; Niedziela-Majka A; Yant SR; Yu H; Kukolj G; Cihlar T; Lazerwith SE; White KL; Jin H
Antimicrob Agents Chemother; 2016 Dec; 60(12):7086-7097. PubMed ID: 27645238
[TBL] [Abstract][Full Text] [Related]
27. Dolutegravir-Selected HIV-1 Containing the N155H and R263K Resistance Substitutions Does Not Acquire Additional Compensatory Mutations under Drug Pressure That Lead to Higher-Level Resistance and Increased Replicative Capacity.
Anstett K; Fusco R; Cutillas V; Mesplède T; Wainberg MA
J Virol; 2015 Oct; 89(20):10482-8. PubMed ID: 26246578
[TBL] [Abstract][Full Text] [Related]
28. HIV drug resistance against strand transfer integrase inhibitors.
Anstett K; Brenner B; Mesplede T; Wainberg MA
Retrovirology; 2017 Jun; 14(1):36. PubMed ID: 28583191
[TBL] [Abstract][Full Text] [Related]
29. Resistance to HIV integrase strand transfer inhibitors: in vitro findings and clinical consequences.
Grobler JA; Hazuda DJ
Curr Opin Virol; 2014 Oct; 8():98-103. PubMed ID: 25128610
[TBL] [Abstract][Full Text] [Related]
30. Authentic HIV-1 integrase inhibitors.
Liao C; Marchand C; Burke TR; Pommier Y; Nicklaus MC
Future Med Chem; 2010 Jul; 2(7):1107-22. PubMed ID: 21426159
[TBL] [Abstract][Full Text] [Related]
31. Antiviral Activity of Bictegravir and Cabotegravir against Integrase Inhibitor-Resistant SIVmac239 and HIV-1.
Hassounah SA; Alikhani A; Oliveira M; Bharaj S; Ibanescu RI; Osman N; Xu HT; Brenner BG; Mesplède T; Wainberg MA
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923862
[TBL] [Abstract][Full Text] [Related]
32. Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir.
Quashie PK; Mesplède T; Han YS; Oliveira M; Singhroy DN; Fujiwara T; Underwood MR; Wainberg MA
J Virol; 2012 Mar; 86(5):2696-705. PubMed ID: 22205735
[TBL] [Abstract][Full Text] [Related]
33. Identification of HIV-1 integrase inhibitors via three-dimensional database searching using ASV and HIV-1 integrases as targets.
Chen IJ; Neamati N; Nicklaus MC; Orr A; Anderson L; Barchi JJ; Kelley JA; Pommier Y; MacKerell AD
Bioorg Med Chem; 2000 Oct; 8(10):2385-98. PubMed ID: 11058033
[TBL] [Abstract][Full Text] [Related]
34. Rational design of 2-pyrrolinones as inhibitors of HIV-1 integrase.
Ma K; Wang P; Fu W; Wan X; Zhou L; Chu Y; Ye D
Bioorg Med Chem Lett; 2011 Nov; 21(22):6724-7. PubMed ID: 21996518
[TBL] [Abstract][Full Text] [Related]
35. Heterocycle amide isosteres: An approach to overcoming resistance for HIV-1 integrase strand transfer inhibitors.
Peese KM; Naidu BN; Patel M; Li C; Langley DR; Terry B; Protack T; Gali V; Lin Z; Samanta HK; Zheng M; Jenkins S; Dicker IB; Krystal MR; Meanwell NA; Walker MA
Bioorg Med Chem Lett; 2020 Feb; 30(3):126784. PubMed ID: 31761656
[TBL] [Abstract][Full Text] [Related]
36. Structure-Guided Optimization of HIV Integrase Strand Transfer Inhibitors.
Zhao XZ; Smith SJ; Maskell DP; Métifiot M; Pye VE; Fesen K; Marchand C; Pommier Y; Cherepanov P; Hughes SH; Burke TR
J Med Chem; 2017 Sep; 60(17):7315-7332. PubMed ID: 28737946
[TBL] [Abstract][Full Text] [Related]
37. The preclinical discovery and development of dolutegravir for the treatment of HIV.
Bailly F; Cotelle P
Expert Opin Drug Discov; 2015; 10(11):1243-53. PubMed ID: 26517818
[TBL] [Abstract][Full Text] [Related]
38. Novel secondary mutations C56S and G149A confer resistance to HIV-1 integrase strand transfer inhibitors.
Yoshinaga T; Seki T; Miki S; Miyamoto T; Suyama-Kagitani A; Kawauchi-Miki S; Kobayashi M; Sato A; Stewart E; Underwood M; Fujiwara T
Antiviral Res; 2018 Apr; 152():1-9. PubMed ID: 29410019
[TBL] [Abstract][Full Text] [Related]
39. Combination of two pathways involved in raltegravir resistance confers dolutegravir resistance.
Malet I; Thierry E; Wirden M; Lebourgeois S; Subra F; Katlama C; Deprez E; Calvez V; Marcelin AG; Delelis O
J Antimicrob Chemother; 2015 Oct; 70(10):2870-80. PubMed ID: 26205139
[TBL] [Abstract][Full Text] [Related]
40. Structure-activity relationships of HIV-1 integrase inhibitors--enzyme-ligand interactions.
Maurin C; Bailly F; Cotelle P
Curr Med Chem; 2003 Sep; 10(18):1795-810. PubMed ID: 12871105
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
